Bruce G. Raphael, MD, discusses the utility of venetoclax and obinutuzumab in chronic lymphocytic leukemia.
Bruce G. Raphael, MD
Advertisement
Articles by Bruce G. Raphael, MD
Bruce G. Raphael, MD, discusses the risk of tumor lysis syndrome in chronic lymphocytic leukemia.
Bruce G. Raphael, MD, a clinical professor in the Department of Medicine at NYU Langone Health, discusses the phase II CLARITY trial in chronic lymphocytic leukemia (CLL).
Bruce G. Raphael, MD, discusses the treatment landscape of chronic lymphocytic leukemia.
Advertisement
Latest Updated Articles
Dr. Raphael on the Treatment Landscape of CLLMarch 2nd 2020
Dr. Raphael on the CLARITY Trial in CLLMarch 9th 2020
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts Third RP1 BLA Resubmission With Nivolumab in Advanced Melanoma
2
From "Not Curable" to "May Be Curable": Joshua Richter, MD, on the New Reality of Multiple Myeloma
3
MAIC Shows OS Benefit With Mogamulizumab vs Vorinostat in Cutaneous T-Cell Lymphoma Subtypes
4
Analysis Identifies Potential Response, Resistance Biomarkers to Mogamulizumab in R/R Mycosis Fungoides/Sézary Syndrome
5